Skip to content

Necitumumab

Portrazza (necitumumab) is an antibody pharmaceutical. Necitumumab was first approved as Portrazza on 2015-11-24. It is used to treat non-small-cell lung carcinoma in the USA. The pharmaceutical is active against epidermal growth factor receptor.
Trade Name Portrazza
Common Name Necitumumab
Indication non-small-cell lung carcinoma
Drug Class Monoclonal antibodies
Necitumumab
Get full access now